Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer’s disease and related dementias by targeting tau self-association. The company’s drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program. Oligomerix’s small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.

Biotechnology

Oligomerix

James Moe

William Erhardt

Robert Foerster

Jack Pasini

Eliot J. Davidowitz

The Leadership Team at Oligomerix drives the strategic vision and operational direction of the company, focusing on the development of innovative therapeutics for Alzheimer’s disease. Comprised of experienced executives, including the CEO, CSO, and CFO, this team oversees research and development, commercialization strategies, financial management, and clinical advancement, ensuring that the company effectively progresses its drug discovery pipeline while fostering collaboration with academic and industry partners.

Leadership Team

Advisory Team

Scientific and Research Team

��

Leadership Team

About

Team members

Other teams at Oligomerix

Advisory Team

Scientific and Research Team

��������

Leadership Team

About

Team members

Other teams at Oligomerix

Advisory Team

Scientific and Research Team

��